AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Perspectives
This section features opinion pieces, reflections, and expert commentary on timely or overlooked issues in cancer care, research, and the oncology workforce.
Asking Because We Care: Why SOGI Data Is Essential to Equitable Cancer Care
By Tiffany Go, MPA, CPCHE
LGBTQ+ patients face real cancer care disparities—and without SOGI data, they remain invisible. A health equity leader at Fred Hutch makes the case for standardized, affirming data collection across cancer care settings.
Asking Because We Care: Why SOGI Data Is Essential to Equitable Cancer Care
By Tiffany Go, MPA, CPCHE
LGBTQ+ patients face real cancer care disparities—and without SOGI data, they remain invisible. A health equity leader at Fred Hutch makes the case for standardized, affirming data collection across cancer care settings.
Asking Because We Care: Why SOGI Data Is Essential to Equitable Cancer Care
By Tiffany Go, MPA, CPCHE
LGBTQ+ patients face real cancer care disparities—and without SOGI data, they remain invisible. A health equity leader at Fred Hutch makes the case for standardized, affirming data collection across cancer care settings.
Triple Negative Breast Cancer in 2026: ADCs Move to the Front, Immunotherapy Stays Central, and Biomarkers Still Lag Behind
By Nikitha Vobugari, MD
ADCs are moving to the front line in metastatic TNBC, immunotherapy's role in early-stage disease is being refined, and biomarkers still lag behind. Dr. Nikitha Vobugari breaks down where the field stands in 2026.
Triple Negative Breast Cancer in 2026: ADCs Move to the Front, Immunotherapy Stays Central, and Biomarkers Still Lag Behind
By Nikitha Vobugari, MD
ADCs are moving to the front line in metastatic TNBC, immunotherapy's role in early-stage disease is being refined, and biomarkers still lag behind. Dr. Nikitha Vobugari breaks down where the field stands in 2026.
Triple Negative Breast Cancer in 2026: ADCs Move to the Front, Immunotherapy Stays Central, and Biomarkers Still Lag Behind
By Nikitha Vobugari, MD
ADCs are moving to the front line in metastatic TNBC, immunotherapy's role in early-stage disease is being refined, and biomarkers still lag behind. Dr. Nikitha Vobugari breaks down where the field stands in 2026.
CAR-T or Bispecific Antibodies First? A Practical Sequencing Guide for Relapsed Multiple Myeloma in 2026
By Sean Maximillian Taasan, MD
CAR-T or bispecific antibodies first? A myeloma specialist breaks down the sequencing evidence, IMWG guidance, and practical factors that should guide treatment decisions in relapsed multiple myeloma in 2026.
CAR-T or Bispecific Antibodies First? A Practical Sequencing Guide for Relapsed Multiple Myeloma in 2026
By Sean Maximillian Taasan, MD
CAR-T or bispecific antibodies first? A myeloma specialist breaks down the sequencing evidence, IMWG guidance, and practical factors that should guide treatment decisions in relapsed multiple myeloma in 2026.
CAR-T or Bispecific Antibodies First? A Practical Sequencing Guide for Relapsed Multiple Myeloma in 2026
By Sean Maximillian Taasan, MD
CAR-T or bispecific antibodies first? A myeloma specialist breaks down the sequencing evidence, IMWG guidance, and practical factors that should guide treatment decisions in relapsed multiple myeloma in 2026.
Belzutifan in 2026: Three Phase 3 Trials, Two Likely Approvals, and One Negative Surprise
By Scott Tykodi, MD, PhD
Three Phase 3 trials of belzutifan in clear cell RCC reported in 2026: two positive results poised for FDA approval, and one frontline surprise that leaves the current standard of care intact.
Belzutifan in 2026: Three Phase 3 Trials, Two Likely Approvals, and One Negative Surprise
By Scott Tykodi, MD, PhD
Three Phase 3 trials of belzutifan in clear cell RCC reported in 2026: two positive results poised for FDA approval, and one frontline surprise that leaves the current standard of care intact.
Belzutifan in 2026: Three Phase 3 Trials, Two Likely Approvals, and One Negative Surprise
By Scott Tykodi, MD, PhD
Three Phase 3 trials of belzutifan in clear cell RCC reported in 2026: two positive results poised for FDA approval, and one frontline surprise that leaves the current standard of care intact.
The Venetoclax Revolution in AML, and Its Limits in MDS: What the PARADIGM and VERONA Trials Mean for Practice
By By Bart L. Scott, MD
The PARADIGM and VERONA trials tell two very different stories about venetoclax in myeloid malignancies—a promising shift in AML treatment and a sobering setback in MDS. A leading expert breaks down both.
The Venetoclax Revolution in AML, and Its Limits in MDS: What the PARADIGM and VERONA Trials Mean for Practice
By By Bart L. Scott, MD
The PARADIGM and VERONA trials tell two very different stories about venetoclax in myeloid malignancies—a promising shift in AML treatment and a sobering setback in MDS. A leading expert breaks down both.
The Venetoclax Revolution in AML, and Its Limits in MDS: What the PARADIGM and VERONA Trials Mean for Practice
By By Bart L. Scott, MD
The PARADIGM and VERONA trials tell two very different stories about venetoclax in myeloid malignancies—a promising shift in AML treatment and a sobering setback in MDS. A leading expert breaks down both.
Ten Years of CAR-T, and Ten More to Come: A Measured Look at What the Next Decade Will Bring
By Sattva S. Neelapu, MD
A CAR-T cell therapy pioneer reflects on a decade of progress and offers measured predictions for 2036—from frontline use and dual-target CARs to in vivo delivery and beyond oncology.
Ten Years of CAR-T, and Ten More to Come: A Measured Look at What the Next Decade Will Bring
By Sattva S. Neelapu, MD
A CAR-T cell therapy pioneer reflects on a decade of progress and offers measured predictions for 2036—from frontline use and dual-target CARs to in vivo delivery and beyond oncology.
Ten Years of CAR-T, and Ten More to Come: A Measured Look at What the Next Decade Will Bring
By Sattva S. Neelapu, MD
A CAR-T cell therapy pioneer reflects on a decade of progress and offers measured predictions for 2036—from frontline use and dual-target CARs to in vivo delivery and beyond oncology.
AI in Breast Diagnostics: Why What We Do With the Tool Matters More Than the Tool Itself
By Benjamin O. Anderson, MD, FACS
Dr. Benjamin O. Anderson explores the promise and limitations of AI in breast diagnostics, emphasizing that patient navigation, infrastructure, and access to care matter more than technology alone.
AI in Breast Diagnostics: Why What We Do With the Tool Matters More Than the Tool Itself
By Benjamin O. Anderson, MD, FACS
Dr. Benjamin O. Anderson explores the promise and limitations of AI in breast diagnostics, emphasizing that patient navigation, infrastructure, and access to care matter more than technology alone.
AI in Breast Diagnostics: Why What We Do With the Tool Matters More Than the Tool Itself
By Benjamin O. Anderson, MD, FACS
Dr. Benjamin O. Anderson explores the promise and limitations of AI in breast diagnostics, emphasizing that patient navigation, infrastructure, and access to care matter more than technology alone.
Interpreting Bladder Cancer Abstracts at GU ASCO 2026 for Real-World Practice
By Jason Brown, MD, PhD
Expert commentary from a genitourinary oncologist on top research from ASCO Genitourinary Cancers Symposium
Interpreting Bladder Cancer Abstracts at GU ASCO 2026 for Real-World Practice
By Jason Brown, MD, PhD
Expert commentary from a genitourinary oncologist on top research from ASCO Genitourinary Cancers Symposium
Interpreting Bladder Cancer Abstracts at GU ASCO 2026 for Real-World Practice
By Jason Brown, MD, PhD
Expert commentary from a genitourinary oncologist on top research from ASCO Genitourinary Cancers Symposium
Key ASH 2025 Updates in Non-Hodgkin Lymphoma
By Madiha Iqbal, MD
Key ASH 2025 updates in non-Hodgkin lymphoma highlight CAR-T durability, bispecific antibody breakthroughs, and new FDA-approved therapies reshaping treatment for DLBCL and follicular lymphoma.
Key ASH 2025 Updates in Non-Hodgkin Lymphoma
By Madiha Iqbal, MD
Key ASH 2025 updates in non-Hodgkin lymphoma highlight CAR-T durability, bispecific antibody breakthroughs, and new FDA-approved therapies reshaping treatment for DLBCL and follicular lymphoma.
Key ASH 2025 Updates in Non-Hodgkin Lymphoma
By Madiha Iqbal, MD
Key ASH 2025 updates in non-Hodgkin lymphoma highlight CAR-T durability, bispecific antibody breakthroughs, and new FDA-approved therapies reshaping treatment for DLBCL and follicular lymphoma.
Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges
By Hun Ju Lee, MD
Expert analysis of how SWOG S1826, nivolumab-based regimens, PET-adapted therapy, and immunotherapy combinations are redefining frontline treatment for classical Hodgkin lymphoma in 2026.
Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges
By Hun Ju Lee, MD
Expert analysis of how SWOG S1826, nivolumab-based regimens, PET-adapted therapy, and immunotherapy combinations are redefining frontline treatment for classical Hodgkin lymphoma in 2026.
Frontline Treatment of Hodgkin Lymphoma in 2026: A New Standard Emerges
By Hun Ju Lee, MD
Expert analysis of how SWOG S1826, nivolumab-based regimens, PET-adapted therapy, and immunotherapy combinations are redefining frontline treatment for classical Hodgkin lymphoma in 2026.